Novel inhibitors of factor X for use in cardiovascular diseases. - Wikidata - awgldk - TriplyDB

Novel inhibitors of factor X for use in cardiovascular diseases.

Novel inhibitors of factor X for use in cardiovascular diseases.

http://www.wikidata.org/entity/Q34027530

about

Anticoagulants and inhibitors of platelet aggregation derived from leeches.Systems pharmacology analysis of synergy of TCM: an example using saffron formula.

P2860

Q34189338-95618EBD-F246-4BFB-A594-17EA9B748BB6 Q49190788-1E788944-6A9E-4B9F-A3A6-D1717072D221

P2860

Novel inhibitors of factor X for use in cardiovascular diseases.

http://www.wikidata.org/entity/Q34027530

description

2000 nî lūn-bûn

@nan

2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Novel inhibitors of factor X for use in cardiovascular diseases.

@ast

Novel inhibitors of factor X for use in cardiovascular diseases.

@en

Novel inhibitors of factor X for use in cardiovascular diseases.

@nl

type

label

Novel inhibitors of factor X for use in cardiovascular diseases.

@ast

Novel inhibitors of factor X for use in cardiovascular diseases.

@en

Novel inhibitors of factor X for use in cardiovascular diseases.

@nl

prefLabel

Novel inhibitors of factor X for use in cardiovascular diseases.

@ast

Novel inhibitors of factor X for use in cardiovascular diseases.

@en

Novel inhibitors of factor X for use in cardiovascular diseases.

@nl

P1433

Q34027530-7D55CF4E-51B9-4A62-BB7A-F234B8A9E105

P1476

Q34027530-638BFCA2-562A-459B-897D-B22CB9F8709E

P2093

Q34027530-00AE4042-434A-45AA-B763-AEF6E6C303F9

Q34027530-E232C3E9-5192-4F8D-A89F-D7002D092EEE

P2860

Q34027530-18ED74A7-9951-4B5A-8EA3-449161ADF5FA

Q34027530-416EAEF1-48DF-4C20-B347-24F13E0B8AF2

Q34027530-93F40B3E-94C2-40B8-902F-2162D518112D

Q34027530-94503A27-6A39-4751-BC96-56E50FA831F3

Q34027530-C4C9F3A5-B13E-4FFA-8084-191BF1C8A5BA

P2888

Q34027530-65853E6C-7C96-4114-9668-1D50381DEC62

P304

Q34027530-AC367A69-64DF-48BD-BA4B-93CA5EFC7285

P31

Q34027530-C92E0E72-3569-4E1A-A532-9A9548CBBCAE

P356

Q34027530-9FF35A0F-CF5E-4CED-AD7B-6F216C275B33

P433

Q34027530-CB761AE5-FE03-4C53-A6DF-FD5F5921B18B

P478

Q34027530-FC03C5B0-375B-488B-8532-01D0D8EF66D9

P577

Q34027530-D3D84D18-F325-482D-83A2-AA39AF537862

P6179

Q34027530-71B6E21C-0375-4276-8331-5809651876A8

P698

Q34027530-FE83436F-7C4B-4FE9-9773-1ADA4082EF5C

P921

Q34027530-1D341171-153B-439D-9BFC-C821F9B2C0F8

P356

S11886-000-0052-Z

P1433

Current cardiology reports

P1476

Novel inhibitors of factor X for use in cardiovascular diseases.

@en

P2093

Becker RC

http://www.w3.org/2001/XMLSchema#string

Spencer FA

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.

New developments in antiplatelet and antithrombotic therapy.

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.

P2888

s11886-000-0052-z

P304

395-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11886-000-0052-Z

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1045785703

http://www.w3.org/2001/XMLSchema#string

P698

10980906

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease